알파만노시도시스 치료는 체내 세포에서 특정 복합 당질을 적절히 분해하지 못하는 것이 특징인 희귀한 유전 질환입니다. 중추신경계를 포함한 많은 신체 기관과 시스템이 당의 축적에 의해 영향을 받습니다. 이 질환의 영향은 사람마다 크게 다릅니다. 알파만노시도시스 치료는 알파-만노시다아제 효소 생성을 암호화하는 MAN2B1 유전자의 변화로 인해 발생합니다.
알파만노시도시스 치료의 중증도는 다양합니다. 발달 지연, 지적 장애, 언어 장애, 난청, 뼈의 변형 등이 대표적인 증상입니다. 알파만노시도시스 치료는 알파만노시다아제 효소를 생산하는 MAN2B1 유전자가 돌연변이를 일으킵니다. 현재 알파만노시도시스 치료법은 없으며, 증상 관리와 지지 요법이 주를 이룹니다.
유럽의약품청(EMA)과 미국 식품의약국(FDA)과 같은 규제 기관은 희귀질환 치료제 개발을 촉진하기 위한 이니셔티브와 인센티브를 제공하고 있습니다. 이러한 이니셔티브는 시장 확대를 지원하는 동시에 업계의 심층적인 연구 개발을 촉진합니다.
예컨대 Chiesi Farmaceutici S.p.A.의 한 부서인 Chiesi Global Rare Diseases에 따르면, 미국 식품의약국(FDA)은 2023년 2월 성인 및 소아 알파만노시도시스(AM) 치료제로 Lamzede( velmanase alfa-tycv)를 승인했습니다. AM은 만노시다아제라는 효소 결핍으로 인해 극히 드문 진행성 리소좀 저장 장애를 일으킵니다.
유전학, 분자생물학 등 의학의 발전으로 이 질환의 메커니즘이 밝혀지고 있습니다. 이러한 정보를 바탕으로 표적화된 의약품이 개발될 수 있을 것입니다. 제약회사, 생명공학 기업, 연구기관들은 희귀질환 치료법 개발을 위해 투자하고 있습니다. 혁신적인 치료법을 시장에 출시하기 위해 자금과 투자는 연구 방법을 가속화하고 임상시험을 신속하게 진행할 수 있습니다.
알파만노시도시스 치료의 관리와 치료를 억제하는 요인은 여러 가지가 있습니다. 예를 들어, 유망한 치료법이 개발되더라도, 특히 의료 자원이 제한적이거나 경제적으로 취약한 지역에서는 치료법에 대한 접근성이 낮을 수 있으며, 희귀 질환 연구에 대한 자금 지원이 제한적이라는 점이 치료의 걸림돌이 될 수 있습니다. 알파만노시도시스 치료의 진단은 희귀성과 증상의 다양성으로 인해 진단이 어렵고, 오진이나 미진단으로 인해 적절한 의료 관리가 지연될 수 있습니다. 시장 규모가 작기 때문에 제약회사는 희귀질환 치료제에 대한 투자 의지가 낮을 수 있습니다.
Alpha-mannosidosis is a rare genetic condition characterized by an inability to properly break down certain groups of complex sugars in the body's cells. Numerous bodily organs and systems, including the central nervous system, are impacted by sugar buildup. The disease's effects might vary greatly from person to person. Alpha-mannosidosis is brought on by changes in the MAN2B1 gene, which codes for the creation of the alpha-mannosidase enzyme.
Individuals with alpha-mannosidosis may have varying degrees of severity. Developmental delays, intellectual challenges, speech problems, hearing loss, and bone deformities are typical signs. The MAN2B1 gene, which gives instructions for producing the alpha-mannosidase enzyme, is mutated in alpha-mannosidosis. There is currently no treatment for alpha-mannosidosis; instead, the focus is on symptom management and supportive care.
Regulatory organisations, such the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), provide initiatives and incentives to promote the development of therapies for rare diseases. These initiatives promote in-depth research and development in the industry while helping market expansion.
For instance, in February 2023, U.S. Food and Drug Administration (FDA) has approved Lamzede (velmanase alfa-tycv) for the treatment of alpha-mannosidosis (AM) in adults and children, according to Chiesi Global Rare Diseases, a division of Chiesi Farmaceutici S.p.A. A lack of the enzyme -mannosidase results in AM, an extremely rare, progressive lysosomal storage disorder.
The mechanisms of the disease have become well-defined because to ongoing developments in medical science, including genetics and molecular biology. The development of targeted medicines may result from such information. Investments are made towards the creation of treatments for rare medical conditions by pharmaceutical companies, biotech companies, and research organisations. In order to bring innovative therapies to market, funding and investment can speed up the research process and make clinical trials quicker.
There are several factors that can restrain the management and treatment of alpha-mannosidosis. For instance, even if promising treatments are developed, it may be difficult to ensure widespread access to them, especially in areas with limited healthcare resources or in economically disadvantaged communities, and limited funding for rare diseases research can hinder this are involved. Diagnosing alpha-mannosidosis can be challenging due to its rarity and the variability in symptoms, and it may be misdiagnosed or undiagnosed, leading to delays in appropriate medical management. Due to the small market size, pharmaceutical companies may be less motivated to invest in treatments for rare diseases.
The global alpha-mannosidosis marketis segmented based on indication, treatment, end user and region.
Certain lysosomal storage disorders, such as Alpha-mannosidosis, are treated medically with enzyme replacement therapy (ERT). A lack of the enzyme alpha-mannosidase results in the rare hereditary condition known as alpha-mannosidosis. The patient is subsequently given the purified and altered enzyme via routine intravenous infusions, frequently in a clinical environment like a hospital or specialised treatment facility. Complex carbohydrates must be broken down by this enzyme in the lysosomes of cells.
It's crucial to stay in mind that ERT is frequently a lifetime treatment. Regular infusions are required to keep the body's enzyme levels stable and to keep the breakdown of stored materials going. Healthcare workers regularly monitor patients receiving ERT. Depending on the patient's response and specific requirements, the dosage and frequency of the infusions may need to be changed.
The largest market share for alpha mannosidosis was held by North America, whose dominance was primarily explained by the greater volume of clinical trials carried out there. Additionally, the region has witnessed a rise in the development of orphan medications. Many orphan drugs are receiving FDA and other regulatory body approvals as a result of such government policies.
Additionally, among the regions, the mannosidosis market in Europe is predicted to grow at the quickest rate. The numerous government attempts to raise public knowledge of rare genetic illnesses and associated therapies have been responsible for the market expansion in Europe.
Over only a short time, the spread of new coronavirus had a rather detrimental effect on the global alpha mannosidosis market. During the pandemic era, the healthcare, pharmaceutical, and other associated industries experienced intense pressure. The number of COVID-19 patients increased to the point where hospitals and clinics were overrun. These facilities' resources were almost entirely devoted to combating the pandemic. This led to the neglect of individuals with other, less serious medical illnesses, such as genetic diseases like alpha mannosidosis.
In addition, a number of governmental and private healthcare organisations prioritised funding the pandemic crisis. This resulted in less money being available for illnesses other than COVID-19. Healthcare service providers are anticipated to concentrate on non-Covid patients with other health conditions as the number of COVID-19 cases declines. In turn, it is projected that this will accelerate market expansion during the post-pandemic period.
major global players in the market include: CHIESI Farmaceutici S.p.A. and Zymenex among others.
The global Alpha-mannosidosis market report would provide approximately 39 tables, 50 figures and 187 Pages.
LIST NOT EXHAUSTIVE